OpenAI expands into drug development with Orchestra Bio acquisition

OpenAI has expanded its work in drug development by buying Orchestra Bio. The company uses AI agents, which are computer systems that can carry out tasks, to help move new treatments from the laboratory to patients.

The deal aims to help scientists organise the research and practical work needed to turn discoveries into new medicines.

Developing a medicine takes an average of 10 to 15 years. This process starts with finding a possible target for a drug and ends with getting approval from regulators in the United States.

The process involves many departments and outside partners. They often use different systems that do not work well together. OpenAI believes AI could help manage this complicated work and give researchers more time to focus on scientific decisions.

Rosalind offers AI models and tools for research in the life sciences, which include biology and other fields that study living things. GPT-Rosalind helps scientists answer questions about biology and chemistry. Rosalind Workbench connects these AI abilities with scientific tools and data to help researchers analyse information and plan experiments.

Orchestra Bio focuses on organising the work needed to move possible treatments through the development process.

Its platform lets scientists and programme leaders hand tasks to AI agents. These tasks can include checking studies and keeping track of research activities.

The agents are designed to help teams spot problems before they cause delays and look at possible ways to deal with them.

For example, a failed batch during manufacturing could delay the start of a clinical trial and affect other activities in a drug development programme.

Orchestra's agents can identify which activities and schedules might be affected, collect useful information and compare possible ways to respond.

Scientists and programme leaders can then use this analysis to decide what to do.

By bringing Orchestra together with Rosalind, OpenAI aims to build AI agents that connect scientific findings with the studies, decisions and next steps needed to develop possible medicines.

The company is also working with pharmaceutical companies to explore how AI can help with research and development.

Its partnership with Novo Nordisk aims to use the pharmaceutical company's size and scientific knowledge to speed up research, development and business operations while maintaining strong oversight and control.

At Moderna, AI is helping teams turn findings from complex data into plans for experiments. This could help speed up research and development.

OpenAI's long-term goal is to help scientists throughout drug discovery and development. This includes exploring research ideas, designing experiments, understanding results and organising the work needed to move treatments forward.

The company hopes that combining Rosalind and Orchestra Bio will help researchers make more discoveries and bring new medicines to patients sooner.